The administration of 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo [3,4-d]pyrimidine (PP2), a Src-family tyrosine kinase inhibitor, diminished the phosphorylation of occludin, and reduced the BBB disruption following cerebral ischemia (Takenaga et al., 2009). The gene discussed is OCLN; the disease is brain ischemia.